These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38036941)

  • 21. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
    Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
    Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Du RC; Ouyang YB; Lu NH; Hu Y
    Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Jung YS; Kim EH; Park CH
    Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
    Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of
    Kanu JE; Soldera J
    World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
    Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
    Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vonoprazan on the Eradication of Helicobacter pylori Infection.
    Huang J; Lin Y
    Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
    Eto H; Suzuki S; Kusano C; Ikehara H; Ichijima R; Ito H; Kawabe K; Kawamura M; Yoda Y; Nakahara M; Gotoda T
    Helicobacter; 2021 Apr; 26(2):e12788. PubMed ID: 33580612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vonoprazan-amoxicillin dual therapy with different amoxicillin dosages for treatment-naive patients of Helicobacter pylori infection in China: a prospective, randomized controlled study.
    Liu Z; Sun D; Kou L; Jia L; Hao J; Zhou J; Zheng W; Gao F; Chen X
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):712-719. PubMed ID: 38526917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vonoprazan-amoxicillin dual therapy for
    Huang XP; Liu YJ; Lin SW; Shao YF; Qiu F; Qiu QW; Xu ZK; Chen JX; Chen LH; Lin ZQ; Dai WH; Zhang MQ; Jiang Q; Xiao ZQ; Cheng XX; Zhang XF; You WB; Chen W; Li LQ; Lin WX; Wang YF; Lai FJ; Chen LQ; Huang ZH; Zheng WQ; Wei JQ; Lin ZH
    World J Gastroenterol; 2024 Jul; 30(27):3304-3313. PubMed ID: 39086752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vonoprazan-Amoxicillin Dual Therapy With Different Amoxicillin Administration Regimens for Helicobacter pylori Treatment: A Randomized Controlled Trial.
    Qiu S; Huang Y; Chen J; Guo Y; Li M; Ding Z; Liang X; Lu H
    Helicobacter; 2024; 29(4):e13118. PubMed ID: 39087868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
    Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
    BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
    Ratana-Amornpin S; Sanglutong L; Eiamsitrakoon T; Siramolpiwat S; Graham DY; Mahachai V
    Helicobacter; 2023 Dec; 28(6):e13019. PubMed ID: 37723133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials.
    Zhang M; Pang M; Zhang M
    Clinics (Sao Paulo); 2022; 77():100058. PubMed ID: 35810638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies.
    Gao W; Xu Y; Liu J; Wang X; Dong X; Teng G; Liu B; Dong J; Ge C; Ye H; Zhang X; Cheng H
    Helicobacter; 2023 Apr; 28(2):e12947. PubMed ID: 36650673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
    Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
    J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
    Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
    Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.